Holen Sie sich die Stockscreener-App
23.86
3.16%
0.73
Handel nachbörslich:
23.86
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
State Street Corp Buys 131,896 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,680 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Earns Coveted Spot in Nasdaq Biotechnology Index, Marking IBD Innovation Leadership - StockTitan
Evercore ISI Group Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - MSN
Jones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold Recommendation - MSN
The Manufacturers Life Insurance Company Has $1.28 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE) - Seeking Alpha
Wellington Management Group LLP Has $44.33 Million Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Charles Schwab Investment Management Inc. Has $9.80 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Eastern Progress Online
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Janus Henderson Group PLC - MarketBeat
61,256 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Cinctive Capital Management LP - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $48.57 - MarketBeat
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies - Yahoo Finance
Spyre begins Phase 1 trials for new IBD treatments By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Fmr LLC - MarketBeat
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PR Newswire
Walleye Capital LLC Increases Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire
SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect - AccessWire
Spyre Therapeutics’ $200 Million Common Stock Offering - Global Legal Chronicle
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect - AccessWire
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation - AccessWire
First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire
Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat
Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN
Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire
Spyre Therapeutics revises net loss per share calculations - Investing.com
Spyre Therapeutics launches $200 million public offering - Investing.com
Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan
Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat
Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com
SYRE Crosses Below Key Moving Average Level - Nasdaq
Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com
Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com
Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat
Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia
FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com
Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World
Spyre reports promising Phase 1 results for IBD therapy - Investing.com India
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):